The Efficacy & Safety of the UAS Immunotherapy Protocol

United Allergy Services

Status: Completed

Conditions: Perennial Allergic Rhinitis With Seasonal Variation

Treatments: Other: allergen immunotherapy

Study type: Observational

Funder types: Industry

Identifiers

NCT01699659

UAS protocol #1 (Other Grant/Funding Number)

Details and patient eligibility

About

Hypothesis: The UAS Immunotherapy protocol is efficacious and at least as efficacious as protocols described in the Allergy literature.

Full description

Patients will be assessed for efficacy of the immunotherapy protocol by completing Consented-IRB approved clinical, medication, quality of life survey questions comparing current status while on therapy in contrast to 12 months before the inception of therapy.

Enrollment: 60 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Allergic rhinitis between 18 and 65 years old who have chosen to undergo immunotherapy.

Exclusion criteria

• No beta blocker use,
• no pregnancy,
• no systemic steroids,
• no severe asthma/copd,
• no severe collagen vascular disorders,
• no neoplastic or uncontrolled seizure activity,
• no previous anaphylaxis, no significant cardiovsacular disease.